Platelia™ *Candida* Ag Plus
Platelia™ *Candida* Ab Plus

When Early Diagnosis Saves Lives

BIO-RAD

Platelia™ *Candida* Ag Plus - Platelia™ *Candida* Ab Plus

Monitoring of patients at-risk for invasive candidiasis

Early diagnosis | Fast initiation of appropriate antifungal treatment

Candida infections rank as the first cause of nosocomial fungal infections; candidemias are the fourth cause of nosocomial blood stream infections.

Invasive candidiasis represent the most serious forms of *Candida* infections with a mortality rate ranging from 30 to 70% in immunosuppressed patients and 30 to 40% in patients hospitalized in intensive care units. Their diagnosis is still difficult due to the lack of specificity of the clinical symptoms and the poor sensitivity of the blood culture. The diagnosis of invasive candidiasis, leading to initiation of appropriate treatment, is usually based on a combination of data: it must associate serological techniques with direct mycological methods. The detection of circulating antigens in serum or plasma appears to improve the diagnosis in patients at risk for invasive candidiasis.

The major risk factors include neutropenia after chemotherapy or immunosuppressive treatment (in cancer, oncohematological and transplant patients), wide spectrum antibiotherapy, venous catheters, parental nutrition, renal dialysis, implanting of prosthesis (in patients hospitalized in medical or surgical intensive care units).

Amongst *Candida* antigens, mannan is a highly immunogenic polysaccharide bound to the yeast cell-wall. It appears to be one of the main biomarkers for the diagnosis of invasive candidiasis.

The regular monitoring of at-risk patients, combining the detection of circulating mannan antigen (Platelia™ *Candida* Ag Plus) and anti-mannan antibodies (Platelia™ *Candida* Ab Plus), is an aid to improve the earliness of the diagnosis of invasive candidiasis. It can help physicians in initiating prompt and appropriate antifungal therapy, resulting in life saving and decreased morbidity.

Simple
- Standard EIA procedure

Flexible
- Serum or plasma samples

Convenient
- 96-well microplate with breakable strips
- Ready-to-use, colored reagents (diluents, calibrators, conjugate, chromogen)

Secured
- Visual control of sample deposit
- Visual control of reagent deposit

Objective
- Results reported as pg/ml(Ag)
- Results reported as AU/ml(Ab)

Quick
- 2h00 (Ag), 2h30 (Ab) turnaround time

Efficient
- Enhanced sensitivity
- Faster initiation of appropriate treatment

Automated
- Fully automated on Bio-Rad Systems: EVOLIS™ Premium, EVOLIS™ *Twin Plus*, PR 3100

Economical
- Improved laboratory workflow
- Hospitalization cost savings

Platelia™ *Candida* Ag Plus Kit

Platelia™ *Candida* Ab Plus Kit

Ordering Information

Catalog No.	Description
62784	Platelia™ *Candida* Ag Plus..... 96 tests
62785	Platelia™ *Candida* Ab Plus..... 96 tests

BIO-RAD **Bio-Rad Laboratories**

For further information, please contact the Bio-Rad office nearest you or visit our website at www.bio-rad.com/diagnostics

Clinical Diagnostics Group

Website *www.bio-rad.com/diagnostics* ***U.S.*** *1-800-2BIO-RAD* ***Australia*** *61-2-9914-2800* ***Austria*** *43-1-877-8901* ***Belgium*** *32-9-385-5511* ***Brazil*** *5521-3237-9400* ***Canada*** *1-514-334-4372* ***China*** *86-21-64260808* ***Czech Republic*** *420-241-430-532* ***Denmark*** *+45-4452-1000* ***Finland*** *358-9-804-22-00* ***France*** *33-1-47-95-60-00* ***Germany*** *+49-(0)89-318-840* ***Greece*** *30-210-7774396* ***Hong Kong*** *852-2789-3300* ***Hungary*** *+ 36-1-459-6100* ***India*** *91-124-4029300* ***Israel*** *972-3-9636050* ***Italy*** *+39-02-216091* ***Japan*** *81-3-6361-7070* ***Korea*** *82-2-3473-4460* ***Mexico*** *52(55)5200-0520* ***The Netherlands*** *+31-318-540666* ***New Zealand*** *64-9-415-2280* ***Norway*** *47-23-38-41-30* ***Poland*** *48-22-3319999* ***Portugal*** *351-21-472-7700* ***Russia*** *7-495-721-14-04* ***Singapore*** *65-6415-3188* ***South Africa*** *27-11-442-85-08* ***Spain*** *34-91-590-5200* ***Sweden*** *46-8-555-127-00* ***Switzerland*** *41-61-717-95-55* ***Thailand*** *662-651-8311* ***United Kingdom*** *+44-(0)20-8328-2000*

Bio-Rad, S.N.C. au capital de 50 000 000 €, Locataire-Gérant, 449 990 712 RCS Nanterre • N° Intracommunautaire FR 62 449 990 712 • Siret 449 990 712 00019